 AMAG's main product, Ferumoxytol was estimated by the company to generate revenue of $71.5 million in 2013.In August 2013, the company received a new U.S. patent for Ferumoxytol, expiring in 2020.In June 2015 the company acquired Cord Blood Registry for $700 million.